Dedicated session + human-AI vendor case studies; CIOMS WG XIV anchor

专设场次 + 人机协同厂商案例；CIOMS WG XIV 为锚点

Smarter tools for safety evaluation; data-science-driven signal mgmt

面向安全性评估的更智能工具；数据科学驱动的信号管理

Risk minimization across lifecycle; guidance-to-action pathways

全生命周期风险最小化；从指南到行动的路径

Short course + FDA benefit-risk lead

短课程 + FDA 获益-风险负责人

FDA/EMA/MHRA policy shifts; emerging-market regulators

FDA/EMA/MHRA 政策变化；新兴市场监管机构

Practical RWE for safety-evidence challenges

用务实 RWE 应对安全性证据挑战

Fit-for-purpose PV for biotech; CSO organizational excellence

面向 biotech 的适配型 PV；CSO 组织卓越

Early-phase human-risk understanding

早期阶段的人体风险理解

The Califf keynote, the FDA/EMA/MHRA policy-shift session, and the Africa/Middle-East regional update all foreground a moving regulatory baseline — staying compliant across jurisdictions is treated as the precondition for everything else.

Califf 主旨、FDA/EMA/MHRA 政策变化场次以及非洲/中东区域更新，都把「不断变化的监管基线」放在最前——跨法域保持合规被视为其他一切的前提。

AuroraPrime: Authoring tools that bake jurisdiction-specific reporting rules into the output are the compliant story regulators want to hear.

AuroraPrime：把各法域报告规则内建进产出的撰写工具，正是监管方想听到的合规叙事。

Two back-to-back sessions push lifecycle risk-minimization and 'turning guidance into action' — the framing is execution, not theory: how teams actually produce and adapt RMP/REMS deliverables.

两场相邻场次聚焦全生命周期风险最小化与「把指南转化为行动」——基调是执行而非理论：团队如何真正产出并迭代 RMP/REMS 交付物。

AuroraPrime: RMP narratives are still hand-written deliverables — AuroraPrime's white space sits exactly on this guidance-to-document bridge.

AuroraPrime：RMP 叙述仍是人工交付物——AuroraPrime 的白地带正落在这条「指南→文档」的桥上。

Three sessions invoke AI — smarter signal-detection tooling, AI transforming PV, and RWE for safety evidence. Tellingly, the language is augmentation ('smarter tools', 'transform'), echoing CIOMS WG XIV's human-in-the-loop guardrail rather than full automation.

三场涉及 AI——更智能的信号检测工具、AI 变革 PV、面向安全的 RWE。值得注意的是其措辞是「增强」（更智能的工具、变革），呼应 CIOMS WG XIV 的人在回路护栏，而非完全自动化。

AuroraPrime: Human-in-the-loop authoring with a full audit trail is precisely the WG XIV-aligned posture these sessions endorse.

AuroraPrime：带完整审计轨迹的人在回路撰写，正是这些场次所认可、契合 WG XIV 的姿态。

A DIAmond session of global Chief Safety Officers plus a fit-for-purpose-PV session for small/emerging companies bracket the audience — from biotech building PV from scratch to the CSOs running best-in-class organizations.

一场全球首席安全官的 DIAmond 场次，加上面向中小/新兴企业的「适配型 PV」场次，框定了受众——从从零搭建 PV 的 biotech，到运营一流组织的 CSO。

AuroraPrime: Both ends of this spectrum feel the aggregate-reporting workload — the exact pain AuroraPrime's authoring layer relieves.

AuroraPrime：这条光谱的两端都承受汇总报告的工作量——正是 AuroraPrime 撰写层要缓解的痛点。

GenAI, NLP and agentic automation applied to case processing, signal management, and narrative authoring across the safety lifecycle.

将 GenAI、NLP 与 agentic 自动化用于安全全生命周期的病例处理、信号管理与叙述撰写。

Adapting RMP/REMS and risk-minimization measures across the product lifecycle; turning guidance into operational action.

在产品全生命周期中调整 RMP/REMS 与风险最小化措施；把指南转化为可执行的行动。

Next-generation tools — disproportionality, data-science models, real-time surveillance — for detecting and validating safety signals.

用于检测与验证安全信号的新一代工具——失衡分析、数据科学模型、实时监测。

FDA/EMA/MHRA policy convergence plus emerging-market regulators (Africa, Middle East) shaping global post-market safety.

FDA/EMA/MHRA 政策趋同，叠加新兴市场监管机构（非洲、中东）共同塑造全球上市后安全。

Structured benefit-risk frameworks for smarter safety decisions across the lifecycle.

用结构化获益-风险框架在全生命周期中做出更明智的安全决策。

Practical RWE/RWD approaches to fill gaps where spontaneous reporting and clinical data fall short.

用务实的 RWE/RWD 方法填补自发报告与临床数据不足的缺口。

Unifying fragmented surveillance, case, and signal data into a single connected safety platform — 'one system, one truth'.

把碎片化的监测、病例与信号数据统一到一个互联的安全平台——「一套系统，一个真相」。